Total Funding
94
78
Total FundingVenture - Series Unknown raised
Growth Score
4 pts
Heat Score
20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
18018
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
- Samuel D. Waksal: FounderPast Role: Equilibre, Founder
About the Company
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases.
TDI01, a highly selective, potent inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) is currently being studied in the United States for the treatment of idiopathic pulmonary
fibrosis (IPF). Graviton anticipates entering human clinical studies in the U.S. in 2021.
